Bibliography: library/10665-258516

The reference for library/10665-258516 (who-iris) and any references extracted from it. library · All references.

Export these 31 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

31 shown

  1. World Health Organization (2017). WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 10: testing providers. World Health Organization.
    10665-258516 · catalogue · link · repository record · source: catalogue/records/10665-258516.dc.json · held: library/10665-258516
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine. 2010;363(27):2587-99.
    · extracted · source: references/10665-258516.sec-013.1.json
  3. RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29(3):331-7.
    · extracted · source: references/10665-258516.sec-013.2.json
  4. Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, et al. HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. J Infect Dis. 2014.
    · extracted · source: references/10665-258516.sec-013.3.json
  5. RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29(3):331-7.
    · extracted · source: references/10665-258516.sec-013.4.json
  6. Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis. 2015;211(8):1211-8.
    · extracted · source: references/10665-258516.sec-013.5.json
  7. Consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2015 (http://apps.who.int/iris/bitstream/10665/179870/1/9789241508926_eng.pdf?ua=1&ua=1).
    · extracted · link · source: references/10665-258516.sec-013.6.json
  8. Guidelines on HIV self-testing and partner notification. Geneva: World Health Organization; 2016 (http://apps.who.int/iris/bitstream/10665/251655/1/9789241549868-eng.pdf?ua=1).
    · extracted · link · source: references/10665-258516.sec-013.7.json
  9. Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013;8(12):e81997.
    · extracted · source: references/10665-258516.sec-013.8.json
  10. Rosenberg NE, Pilcher CD, Busch MP, Cohen MS. How can we better identify early HIV infections? Curr Opin HIV AIDS. 2015;10(1):61-8.
    · extracted · source: references/10665-258516.sec-013.9.json
  11. Conway DP, Holt M, McNulty A, Couldwell DL, Smith DE, Davies SC, et al. Multi-centre evaluation of the Determine HIV Combo assay when used for point of care testing in a high risk clinic-based population. PLoS One. 2014;9(4):e94062.
    · extracted · source: references/10665-258516.sec-013.10.json
  12. Duong YT, Mavengere Y, Patel H, Moore C, Manjengwa J, Sibandze D, et al. Poor performance of the determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a National Household Survey in Swaziland. J Clin Microbiol. 2014;52(10):3743-8.
    · extracted · source: references/10665-258516.sec-013.11.json
  13. Jones CB, Kuldanek K, Muir D, Phekoo K, Black A, Sacks R, et al. Clinical evaluation of the Determine HIV-1/2 Ag/Ab Combo test. J Infect Dis. 2012;206(12):1947-9; author reply 9-50.
    · extracted · source: references/10665-258516.sec-013.12.json
  14. Lewis JM, Macpherson P, Adams ER, Ochodo E, Sands A, Taegtmeyer M. Field accuracy of fourth-generation rapid diagnostic tests for acute HIV-1: a systematic review. AIDS. 2015;29(18):2465-71.
    · extracted · source: references/10665-258516.sec-013.13.json
  15. Rosenberg NE, Kamanga G, Phiri S, Nsona D, Pettifor A, Rutstein SE, et al. Detection of acute HIV infection: a field evaluation of the determine(R) HIV-1/2 Ag/Ab combo test. J Infect Dis. 2012;205(4):528-34.
    · extracted · source: references/10665-258516.sec-013.14.json
  16. Smallwood M, Vijh R, Nauche B, Lebouche B, Joseph L, Pant Pai N. Evaluation of a Rapid Point of Care Test for Detecting Acute and Established HIV Infection, and Examining the Role of Study Quality on Diagnostic Accuracy: A Bayesian Meta-Analysis. PLoS One. 2016;11(2):e0149592.
    · extracted · source: references/10665-258516.sec-013.15.json
  17. Guanira JV, Leigler T, Kallas E, Schechter M, Sharma U, Glidden D, et al. Streamlining HIV testing for HIV preexposure prophylaxis. J Clin Microbiol. 2015;53(1):179-83.
    · extracted · source: references/10665-258516.sec-013.16.json
  18. HIV drug resistance surveillance guidance, 2015 update. Geneva: World Health Organization; 2015 (http://www.who.int/hiv/pub/drugresistance/hiv-drug-resistance-2015-update/en/).
    · extracted · link · source: references/10665-258516.sec-013.17.json
  19. WHO manual for HIV drug resistance testing using dried blood spot specimens. Geneva: World Health Organization; 2012 (http://www.who.int/hiv/pub/drugresistance/dried_blood_spots/en/).
    · extracted · link · source: references/10665-258516.sec-013.18.json
  20. Knox D, Tan D, Harrigan P, Anderson P. HIV-1 Infection With Multiclass Resistance Despite Preexposure Prophylaxis (PrEP). Presented at: CROI; Boston; 2016.
    · extracted · source: references/10665-258516.sec-013.19.json
  21. Grossman H et al. Newly Acquired HIV-1 Infection with Multi-Drug Resistant (MDR) HIV-1 in a Patient on TDF/FTC-based PrEP. HIV Research for Prevention (HIVR4P) 2016 conference, Chicago, October 2016, abstract OA03.06LB.
    · extracted · source: references/10665-258516.sec-013.20.json
  22. Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851-9.
    · extracted · source: references/10665-258516.sec-013.21.json
  23. Mandala J, Nanda K, Wang M, De Baetselier I, Deese J, Lombaard J, et al. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacol Toxicol. 2014;15(1):77.
    · extracted · source: references/10665-258516.sec-013.22.json
  24. Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, et al. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr. 2016;71(4):374-80.
    · extracted · source: references/10665-258516.sec-013.23.json
  25. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5):e27.
    · extracted · source: references/10665-258516.sec-013.24.json
  26. Solomon MM, Schechter M, Liu AY, McManhan VM, Guanira JV, Hance RJ, et al. The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. J Acquir Immune Defic Syndr. 2016;71(3):281-6.
    · extracted · source: references/10665-258516.sec-013.25.json
  27. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017 http://apps.who.int/iris/bitstream/10665/254621/1/9789241549981-eng.pdf?ua=1.
    · extracted · link · source: references/10665-258516.sec-013.26.json
  28. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf
    · extracted · link · source: references/10665-258516.sec-013.27.json
  29. Mugo NR, Heffron R, Donnell D, Wald A, Were EO, Rees H, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS. 2011;25(15):1887-95.
    · extracted · source: references/10665-258516.sec-013.28.json
  30. Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. Geneva: World Health Organization; 2013 (http://apps.who.int/iris/bitstream/10665/85343/1/9789241505840_eng.pdf?ua=1).
    · extracted · link · source: references/10665-258516.sec-013.29.json
  31. WHO guidelines for the treatment of Treponema pallidum (syphilis). Geneva: World Health Organization; 2016 http://apps.who.int/iris/bitstream/10665/249572/1/9789241549806-eng.pdf?ua=1.
    · extracted · link · source: references/10665-258516.sec-013.30.json